Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using positron emission tomography to facilitate CNS drug development.

Chi-Ming Lee1, Lars Farde

  • 1AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850, USA. chi-ming.lee@astrazeneca.com

Trends in Pharmacological Sciences
|May 9, 2006
PubMed
Summary

Positron emission tomography (PET) enables precise tracking of radiolabeled drugs in the body, even at microdoses. This nuclear medicine technique aids in mapping drug distribution, assessing brain exposure, and studying disease biomarkers like amyloid plaques.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Binding of the High Affinity Radioligand Fallypride to the D2-dopamine Receptor is Sensitive to Injected Mass - a PET Study in Rodents.

Molecular imaging and biology·2026
Same author

Transbronchial photodynamic therapy for peripheral lung cancer - A pilot study.

Photodiagnosis and photodynamic therapy·2026
Same author

Quantification of pituitary 5-HT<sub>1B</sub> receptors with positron emission tomography: Negligible specific binding despite conspicuous uptake.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Emergency total extracorporeal life support versus standard advanced cardiac life support with rescue extracorporeal membrane oxygenation for refractory out-of-hospital cardiac arrest: protocol for the ECLS-OHCA randomized trial.

Scandinavian journal of trauma, resuscitation and emergency medicine·2026
Same author

Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391.

Neuro-oncology·2025
Same author

Brain exposure of the mesenchymal-epithelial transition inhibitor savolitinib in nonhuman primates: A positron emission tomography study.

The Journal of pharmacology and experimental therapeutics·2025

Area of Science:

  • Nuclear Medicine
  • Radiochemistry
  • Pharmacology

Background:

  • Positron emission tomography (PET) is a sensitive nuclear medicine imaging technique.
  • It allows for the detection of low picomolar concentrations of radiolabeled molecules.
  • PET is valuable for in vivo tracing and quantitative studies.

Purpose of the Study:

  • To highlight the utility of PET in drug development and clinical research.
  • To demonstrate PET's role in mapping drug distribution and brain exposure.
  • To showcase PET's application in disease biomarker monitoring and personalized medicine.

Main Methods:

  • Radiolabeling drugs to high specific radioactivity for microdose administration.
  • Developing radioligands for quantitative PET studies of drug-target interactions.

Related Experiment Videos

  • Utilizing PET for longitudinal studies of disease progression and treatment outcomes.

    • Main Results:

    • PET facilitates detailed mapping of drug distribution to critical organs, including the brain.
    • It enables the correlation of receptor occupancy with pharmacodynamic responses.
    • PET allows for longitudinal monitoring of biomarkers, such as amyloid plaque load in Alzheimer's disease.

    Conclusions:

    • PET is a powerful tool for early-stage drug development, requiring minimal toxicology data.
    • It offers insights into central nervous system (CNS) drug exposure and target engagement.
    • Combining PET with genomics may identify genetic predictors for personalized drug responses.